Carol Ashe
Directeur/Membre du Conseil chez APTOSE BIOSCIENCES INC.
Fortune : 1 215 $ au 30/06/2024
Profil
Carol G.
Ashe is currently an Independent Director at Aptose Biosciences, Inc. and Elicio Therapeutics, Inc. (United States).
She also holds the position of Chief Business Officer at New York Genome Center.
Previously, she served as Vice President-Corporate Development at Endo International Plc from 2011 to 2013.
She was a Partner at GSK Equity Investments Ltd.
from 2009 to 2010.
From 1995 to 2008, she worked at GSK Plc as the Head-US Corporate Legal Group.
Ms. Ashe completed her undergraduate studies at The Pennsylvania State University and obtained her graduate degree from Villanova University School of Law.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
APTOSE BIOSCIENCES INC.
0,01% | 29/04/2024 | 1 601 ( 0,01% ) | 1 215 $ | 30/06/2024 |
ELICIO THERAPEUTICS, INC
-.--% | 10/04/2024 | 0 ( -.--% ) | - $ | 30/06/2024 |
Postes actifs de Carol Ashe
| Sociétés | Poste | Début |
|---|---|---|
| APTOSE BIOSCIENCES INC. | Directeur/Membre du Conseil | 15/08/2018 |
| ELICIO THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/08/2020 |
New York Genome Center
 New York Genome Center Miscellaneous Commercial ServicesCommercial Services New York Genome Center operates as an independent, nonprofit academic research institution that provides genomic research. It provides research on neurodegenerative disease, neuropsychiatric disease, and cancer. The company was founded in 2011 and is headquartered in New York, NY. | Corporate Officer/Principal | 01/01/2014 |
Elicio Therapeutics, Inc. (Old)
 Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | 01/01/2020 |
Anciens postes connus de Carol Ashe
| Sociétés | Poste | Fin |
|---|---|---|
| ENDO INTERNATIONAL PLC | Corporate Officer/Principal | 01/01/2013 |
GSK Equity Investments Ltd.
 GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | Private Equity Investor | 30/03/2010 |
| GSK PLC | Corporate Officer/Principal | 01/01/2008 |
Formation de Carol Ashe
| The Pennsylvania State University | Undergraduate Degree |
| Villanova University School of Law | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| APTOSE BIOSCIENCES INC. | Health Technology |
| GSK PLC | Health Technology |
| ELICIO THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
GSK Equity Investments Ltd.
GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | Finance |
New York Genome Center
New York Genome Center Miscellaneous Commercial ServicesCommercial Services New York Genome Center operates as an independent, nonprofit academic research institution that provides genomic research. It provides research on neurodegenerative disease, neuropsychiatric disease, and cancer. The company was founded in 2011 and is headquartered in New York, NY. | Commercial Services |
Endo International Plc
 Endo International Plc Pharmaceuticals: MajorHealth Technology Endo International Plc operates as a pharmaceutical company, which engages in the development, manufacture, and distribution of branded and generic pharmaceutical products. It operates through the following segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. The Branded Pharmaceuticals segment conducts certain operations in the U.S. through leased and owned manufacturing properties in Pennsylvania, New York and New Jersey, as well as certain administrative and R&D functions through leased properties in Pennsylvania. The Sterile Injectables segment includes manufacturing, quality assurance, research and development, and administration functions. The Generic Pharmaceuticals segment is composed of manufacturing, distribution, quality assurance and administration functions, as well as certain research and development functions. The International Pharmaceuticals segment’s operations are currently conducted through Paladin’s leased headquarters in Montreal, Canada. The company was founded in 1997 and is headquartered Dublin, Ireland. | Health Technology |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | Health Technology |
